Cost of Revenue Comparison: Amgen Inc. vs Geron Corporation

Cost of Revenue: Amgen Inc. vs. Geron Corporation

In the competitive landscape of biotechnology, understanding cost structures is crucial. Amgen Inc., a titan in the industry, has consistently demonstrated robust financial management. From 2014 to 2023, Amgen's cost of revenue has shown a significant upward trend, peaking at approximately $8.4 billion in 2023, marking a 90% increase from 2014. This reflects Amgen's strategic investments in production and operational efficiencies.

In contrast, Geron Corporation, a smaller player, has experienced more volatility. Despite a notable spike in 2023, where costs surged to $123.7 million, Geron's cost of revenue remains a fraction of Amgen's, highlighting the scale difference between the two companies. This disparity underscores the diverse strategies and market positions within the biotech sector.

The data reveals the dynamic nature of cost management in biotechnology, offering insights into how companies navigate financial challenges over time.